四环医药旗下惠升生物：羟苯磺酸钙胶囊获批，2023年国内销售额达2.55亿元

和讯网06-27

快讯正文【四环医药旗下惠升生物研发的羟苯磺酸钙胶囊获药品注册证书】四环医药宣布，其非全资附属公司惠升生物制药股份有限公司研发的羟苯磺酸钙胶囊已获得国家药品监督管理局颁发的药品注册证书，该产品通过仿制药质量和疗效一致性评价。羟苯磺酸钙作为毛细血管保护剂，用于改善微血管微循环，调节微血管壁的生理功能，增加通透性，降低阻力，降低血浆黏度，预防血栓形成，提高红细胞的柔韧性。该药物是中国临床指南推荐用于改善...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2446309280?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-27 13:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2446309280","market":"hk","top_or_hot":-1,"title":"四环医药旗下惠升生物：羟苯磺酸钙胶囊获批，2023年国内销售额达2.55亿元","media":"和讯网","content":"<div>\n<p>快讯正文【四环医药旗下惠升生物研发的羟苯磺酸钙胶囊获药品注册证书】四环医药宣布，其非全资附属公司惠升生物制药股份有限公司研发的羟苯磺酸钙胶囊已获得国家药品监督管理局颁发的药品注册证书，该产品通过仿制药质量和疗效一致性评价。羟苯磺酸钙作为毛细血管保护剂，用于改善微血管微循环，调节微血管壁的生理功能，增加通透性，降低阻力，降低血浆黏度，预防血栓形成，提高红细胞的柔韧性。该药物是中国临床指南推荐用于改善...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271511359f6ace0f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>四环医药旗下惠升生物：羟苯磺酸钙胶囊获批，2023年国内销售额达2.55亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n四环医药旗下惠升生物：羟苯磺酸钙胶囊获批，2023年国内销售额达2.55亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-27 13:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271511359f6ace0f&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>快讯正文【四环医药旗下惠升生物研发的羟苯磺酸钙胶囊获药品注册证书】四环医药宣布，其非全资附属公司惠升生物制药股份有限公司研发的羟苯磺酸钙胶囊已获得国家药品监督管理局颁发的药品注册证书，该产品通过仿制药质量和疗效一致性评价。羟苯磺酸钙作为毛细血管保护剂，用于改善微血管微循环，调节微血管壁的生理功能，增加通透性，降低阻力，降低血浆黏度，预防血栓形成，提高红细胞的柔韧性。该药物是中国临床指南推荐用于改善...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271511359f6ace0f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271511359f6ace0f&s=b","article_id":"2446309280","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271511359f6ace0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2446309280","pubTimestamp":1719464625,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"快讯正文四环医药宣布，其非全资附属公司惠升生物制药股份有限公司研发的羟苯磺酸钙胶囊已获得国家药品监督管理局颁发的药品注册证书，该产品通过仿制药质量和疗效一致性评价。该药物是中国临床指南推荐用于改善糖尿病微循环的药物，并被列入国家医保乙类药物。2021年中国糖尿病患者约1.4亿人，其中约20%~40%会发生糖尿病视网膜病变。据药智网数据，2023年羟苯磺酸钙口服制剂在国内公立医院的销售收入达到人民币2.55亿元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00460":"四环医药","BK1600":"工业大麻","BK1191":"制药","BK1515":"抗疫概念","BK1593":"医美概念股"},"translate_title":"Huisheng Biology, a subsidiary of Sihuan Pharmaceutical: Calcium dobesilate capsules approved, domestic sales will reach 255 million yuan in 2023","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"快讯正文【四环医药旗下惠升生物研发的羟苯磺酸钙胶囊获药品注册证书】四环医药宣布，其非全资附属公司惠升生物制药股份有限公司研发的羟苯磺酸钙胶囊已获得国家药品监督管理局颁发的药品注册证书，该产品通过仿制药质量和疗效一致性评价。羟苯磺酸钙作为毛细血管保护剂，用于改善微血管微循环，调节微血管壁的生理功能，增加通透性，降低阻力，降低血浆黏度，预防血栓形成，提高红细胞的柔韧性。该药物是中国临床指南推荐用于改善糖尿病微循环的药物，并被列入国家医保乙类药物。2021年中国糖尿病患者约1.4亿人，其中约20%~40%会发生糖尿病视网膜病变。据药智网数据，2023年羟苯磺酸钙口服制剂在国内公立医院的销售收入达到人民币2.55亿元。惠升生物是四环医药旗下专注于糖尿病及并发症领域的生物医药公司，已发展成为国内少数能够实现糖尿病及并发症领域全产品覆盖的全产业链生物制药公司。公司拥有四十余款在研产品，涵盖多种糖尿病治疗药物。四环医药成立于2001年，2010年在香港联合交易所主板上市，致力于打造中国领先的医美及生物制药企业，坚持推进医美及生物制药双轮驱动战略。下载和讯APP查看快讯，体验更佳>>","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446309280"}